查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
2018844

動物疫苗市場：2026-2032年全球市場預測（依產品類型、目標動物、疾病、給藥途徑及通路分類）

Animal Vaccines Market by Product, Animal Type, Disease Type, Route of Administration, Distribution Channel - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 198 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，動物疫苗市場價值將達到 145.8 億美元，到 2026 年將成長到 155.3 億美元，到 2032 年將達到 234 億美元，複合年成長率為 6.99%。

主要市場統計數據
基準年 2025 145.8億美元
預計年份：2026年 155.3億美元
預測年份 2032 234億美元
複合年成長率 (%) 6.99%

明確、有策略地組織科學進步、相關人員的壓力和業務需求，以重新定義動物疫苗開發和部署的優先事項。

動物疫苗產業正處於一個關鍵的轉折點，科學創新、疾病動態變化以及相關人員期望的不斷演變在此交匯融合，重塑著生產者、獸醫和政策制定者的優先事項。分子生物學和免疫學的最新進展正在加速下一代治療方法的研發，而伴侶動物和牲畜疾病預防需求的日益成長，也使得建立強大的疫苗組合變得尤為重要。相關人員面臨著日益嚴格的監管、動物福利方面的倫理考慮以及成本效益和分銷靈活性等商業性需求的複雜博弈。貿易政策的變化、供應鏈的脆弱性以及對抗菌藥物合理使用的日益嚴格的審查，進一步加劇了這些壓力，所有這些都使得以疫苗主導的預防策略成為永續動物健康計劃的核心。

平台創新、數位監控和不斷變化的監管預期如何推動動物免疫策略進入一個準確性、可及性和韌性的新時代。

在科學突破、數位科技應用和不斷變化的流行病學壓力的驅動下，動物疫苗領域正經歷著一場變革。 mRNA和重組技術等平台技術正從實驗階段走向應用特定領域，實現更快的抗原設計和更精準的免疫調節。同時，去活化疫苗和減毒活病毒疫苗等傳統方法也在安全性和熱穩定性方面進行最佳化，以應對長期存在的配送難題。從基因組監測到供應鏈分析和遠端醫療數位工具，使得疫情能夠更早被發現，疫苗接種宣傳活動能夠更快地展開，進而改變著生產商的生產週期和配送方式。

2025 年關稅調整帶來的連鎖營運和策略影響正在重建整個動物疫苗價值鏈的採購、在地化生產和分銷的韌性。

美國在2025年實施的關稅調整對整個動物疫苗價值鏈產生了多方面的影響，包括籌資策略、生產經濟效益和全球貿易流動。某些原料和成品生技藥品的關稅上調促使製造商重新評估其供應商所在地，並加快關鍵生產過程的近岸外包和本地化。這些變化並非僅僅出於成本考量；它們也體現了確保疫苗生產基礎——佐劑、管瓶和特殊試劑等敏感生物成分的持續供應的戰略重點。因此，各組織正在優先考慮建立雙重採購安排和選擇新​​的契約製造合作夥伴，以減少對單一供應商的依賴。

將產品模式、動物類別、目標疾病、給藥途徑和分銷管道進行綜合細分的框架，將有助於實現差異化的開發和商業化方法。

市場區隔揭示了疫苗研發、應用和商業化的獨特動態，每種情況都需要針對產品類型、目標動物、疾病類別、給藥途徑和通路製定量身定做的策略。按產品分類，該領域包括去活化疫苗、減毒活病毒疫苗、mRNA疫苗、重組疫苗和次單位疫苗，每種疫苗的研發週期、生產複雜性和對低溫運輸的依賴程度各不相同。這些差異有助於確定研發管線投資的優先順序和生產力計畫。依動物種類分類，市場涵蓋伴侶動物和家畜。伴侶動物類別進一步細分為貓和狗，而家畜類別則進一步細分為牛、家禽、羊和豬。這種細分突顯了家養寵物和生產動物在臨床需求、給藥方法和分銷模式方面的顯著差異，進而導致了不同的銷售管道和傳播策略。

區域優先事項和基礎設施現狀正在推動美洲、歐洲、中東和非洲以及亞太地區在政策、製造和分銷策略方面出現差異。

區域趨勢反映了管理體制、生產能力、疾病流行程度和分銷基礎設施的差異，從而影響疫苗研發者、經銷商和政策制定者的策略重點。在美洲，重點在於監管協調、低溫運輸現代化以及官民合作關係，以滿足伴侶動物和牲畜的疫苗接種需求。該地區的監管機構優先考慮疫苗的安全性和有效性，而行業相關人員則致力於透過生產自動化和與監測數據相聯繫的精準疫苗接種計劃來提高生產效率。區域內的跨境貿易促進了一體化生產基地的形成，但近期政策的轉變正在推動供應多元化，以降低外部衝擊的影響。

市場領先的公司和敏捷的創新者正在透過建立夥伴關係、確保專業製造能力和整合服務，將技術優勢轉化為永續的商業性地位。

動物疫苗產業的競爭格局由跨國公司、專業生物技術創新企業和提供靈活生產能力的契約製造(CMO) 組成。成熟的大型企業持續投資於產品組合多元化和生產韌性，力求在去活化疫苗和減毒活病毒疫苗等傳統平台與 mRNA 和重組構建體等新興技術之間取得平衡。新興的專業生物技術參與企業正在開發特定適應症和平台能力，通常與 CDMO 合作以快速擴大生產規模並降低資本密集型設施建設的風險。同時，契約製造和服務供應商透過提供模組化、目標明確的生產能力，縮短產品上市時間並支援在地化工作，從而發揮日益重要的策略作用。

製造商和相關人員面臨的可操作的策略挑戰，包括加速創新、實現生產多元化以及加強監管和商業夥伴關係，以增強疫苗供應的韌性。

產業領導者應採取多管齊下的策略，加速技術應用，同時加強供應鏈冗餘和相關人員的協作。首先，他們應優先投資於可重複應用於多種疾病適應症的平台無關型研發，以最大限度地提高科學進步的投資回報並縮短實用化時間。其次，他們應透過認證跨區域的多家契約製造製造商，並選擇性地投資於模組化、一次性使用的技術，建立靈活的生產網路，從而實現快速規模化生產並縮短換線時間。第三，他們應在分散的供應環境中擴大產品可及性，在設計配方和包裝時充分考慮實際分銷限制，並強調熱穩定性和簡化給藥途徑。

經過驗證的多方面研究途徑，結合相關人員訪談、技術文獻綜述以及供應鏈和政策分析，能夠產生基於現實世界實踐的實用見解。

本綜合報告採用三角測量調查方法，結合與關鍵相關人員的對話、技術文獻綜述以及供應鏈和政策分析，以確保提供可靠且可操作的見解。報告以與獸醫、疫苗研發人員、契約製造和分銷通路負責人進行的結構化訪談為主要資訊來源，旨在了解實際情況、未滿足的需求和戰略意圖。此外，報告還查閱了技術文獻和監管指導文件，以檢驗影響疫苗研發和核准的科學趨勢、劑量方面的考慮以及最新進展。

簡要概述如何將創新、政策轉變和實際韌性結合起來，以最大限度地發揮疫苗在保護動物健康和公共安全方面的潛力。

科學創新、貿易政策轉變以及區域性疾病壓力之間的相互作用，既給動物疫苗生態系統帶來了挑戰，也帶來了機會。平台技術和製劑科學的進步為更有效、更容易取得的疫苗鋪平了道路，但這些成就必須輔以對生產柔軟性、分銷韌性和與監管機構合作的投資。關稅政策和地緣政治因素的變化凸顯了供應多元化和區域生產能力的戰略重要性，而不斷變化的終端用戶期望則要求產品不僅有效，而且能夠在實際獸醫環境中切實可行。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章 動物疫苗市場：依產品分類

  • 去活化疫苗
  • 減毒活病毒疫苗
  • 藥效疫苗
  • 重組疫苗
  • 次單位疫苗

第9章 動物疫苗市場：依動物類型分類

  • 伴侶動物
    • 貓
    • 狗
  • 家畜
    • 牛
    • 家禽
    • 羊
    • 豬

第10章：動物疫苗市場：依疾病類型分類

  • 細菌感染疾病
    • 梭狀芽孢桿菌
    • 大腸桿菌
    • 鉤端螺旋體病
    • 巴斯德氏菌
  • 黴菌感染疾病
  • 寄生蟲感染疾病
    • 體外寄生蟲
    • 體內寄生蟲
  • 病毒感染疾病
    • 禽流感病毒
    • 牛病毒性腹瀉病毒（BVDV）
    • 口蹄疫病毒（FMDV）
    • 新城疫病毒
    • 豬繁殖與呼吸綜合症病毒（PRRSV）
    • 狂犬病毒

第11章 動物疫苗市場：依給藥途徑分類

  • 注射疫苗
    • 肌肉內注射（IM）
    • 靜脈注射（IV）
    • 皮下（SC）
  • 口服疫苗

第12章 動物疫苗市場：依通路分類

  • 網路藥房
  • 零售藥房
  • 動物醫院

第13章 動物疫苗市場：依地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第14章 動物疫苗市場：依類別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第15章 動物疫苗市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第16章：美國動物疫苗市場

第17章：中國動物疫苗市場

第18章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • Biogenesis Bago SA
  • BioVaxys Technology Corporation
  • Boehringer Ingelheim International GmbH
  • Brilliant Bio Pharma Private limited
  • Ceva Sante Animale
  • China Animal Husbandry Industry Co., Ltd.
  • Dalan Animal Health
  • Elanco Animal Health Inc.
  • Endovac Animal Health, LLC by Immvac Inc.
  • Hester Biosciences Limited
  • HIPRA, SA
  • Indian Immunologicals Limited
  • Kemin Industries, Inc.
  • Merck KGaA
  • Neogen Corporation
  • Phibro Animal Health Corporation
  • SAN Vet Holding GmbH
  • Sanofi SA
  • Seppic SA
  • Torigen Pharmaceuticals Inc.
  • Vaxxinova GmbH
  • VEROVACCiNES GmbH
  • Vetigenics, LLC
  • Vetoquinol SA
  • Virbac, Inc.
  • Zoetis Inc.
Product Code: MRR-ED54C46E8F03

The Animal Vaccines Market was valued at USD 14.58 billion in 2025 and is projected to grow to USD 15.53 billion in 2026, with a CAGR of 6.99%, reaching USD 23.40 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 14.58 billion
Estimated Year [2026] USD 15.53 billion
Forecast Year [2032] USD 23.40 billion
CAGR (%) 6.99%

A clear, strategic framing of scientific progress, stakeholder pressures, and operational imperatives that redefine priorities for animal vaccine development and deployment

The animal vaccines sector sits at a pivotal junction where scientific innovation, shifting disease dynamics, and evolving stakeholder expectations converge to reshape priorities for manufacturers, veterinarians, and policymakers. Recent advances in molecular biology and immunology have accelerated the development of next-generation modalities, while rising demand for disease prevention across companion animals and livestock has intensified the need for robust vaccine portfolios. Stakeholders face a complex mix of regulatory rigor, ethical considerations around animal welfare, and the commercial imperatives of cost-efficiency and distribution agility. These pressures are compounded by changing trade policies, supply chain vulnerabilities, and heightened scrutiny on antimicrobial stewardship, all of which place vaccine-driven prevention strategies at the center of sustainable animal health programs.

Against this backdrop, organizations must synthesize scientific opportunities with pragmatic delivery models to ensure vaccines reach the animals that need them most. Strategic actors will prioritize translational research that shortens the time from discovery to field deployment, invest in cold-chain and alternative administration routes to improve access, and engage proactively with regulators to de-risk development pathways. In short, the introduction underscores a clear imperative: to transform technical progress into scalable, resilient immunization solutions that align with the operational realities of veterinary care and livestock production.

How platform innovations, digital surveillance, and evolving regulatory expectations are catalyzing a new era of precision, access, and resilience in animal immunization strategies

The landscape of animal vaccines is undergoing transformative shifts driven by scientific breakthroughs, digital-enabled practices, and changing epidemiological pressures. Platform technologies such as mRNA and recombinant approaches are moving from experimental phases into targeted applications, enabling faster antigen design and more precise immune modulation. At the same time, traditional modalities like inactivated and live attenuated vaccines continue to be optimized for safety profiles and thermostability, addressing long-standing distribution challenges. Digital tools-from genomic surveillance to supply chain analytics and telemedicine-are enabling earlier detection of outbreaks and more responsive vaccination campaigns, which in turn alter how manufacturers plan production cycles and distribution.

Clinically, the interplay between zoonotic risk awareness and the intensification of livestock production has intensified demand for vaccines that confer broader protection and longer durability. Regulatory bodies are gradually adapting frameworks to accommodate novel technologies while maintaining rigorous safety standards, prompting proactive engagement by developers to streamline approval paths. Meanwhile, end-users such as veterinarians and producers are demanding vaccines that offer clear returns in terms of herd or companion animal health outcomes, ease of administration, and compatibility with antimicrobial stewardship goals. Together, these forces are reshaping investment priorities, compelling incumbents and new entrants alike to align R&D strategies with scalable manufacturing, improved cold-chain solutions, and integrated data-driven services that amplify vaccine impact.

The cascading operational and strategic consequences of 2025 tariff changes that are reshaping sourcing, manufacturing localization, and distribution resilience across the animal vaccine value chain

United States tariff adjustments enacted in 2025 have created layered effects across the animal vaccine value chain, influencing sourcing strategies, production economics, and global trade flows. Increased duties on select inputs and finished biologics have incentivized manufacturers to reassess supplier footprints and to accelerate near-shoring or regionalization of critical production steps. These shifts are not merely cost-driven; they also reflect a strategic emphasis on controlling supply continuity for sensitive biologic components that underpin vaccine manufacturing, such as adjuvants, vials, and specialized reagents. As a result, organizations are prioritizing dual-sourcing arrangements and qualifying additional contract manufacturing partners to reduce single-point dependencies.

Trade policy changes have also affected distribution planning. Higher cross-border costs have encouraged distributors and veterinary services to optimize inventory strategies, extend product shelf-life through formulation improvements, and explore alternative channels that reduce transit complexity. For exporters, tariff volatility has required more sophisticated pricing and contractual frameworks to maintain competitiveness in key regions, while importers have negotiated long-term supply agreements to mitigate exposure to abrupt tariff swings. Importantly, tariff-induced pressures have heightened interest in domestic capacity building, prompting public-private discussions around incentives for localized vaccine production and workforce development. Collectively, these responses are shaping a more resilient but regionally differentiated production and distribution landscape for animal vaccines.

A comprehensive segmentation framework that aligns product modalities, animal categories, disease targets, administration routes, and distribution channels to inform differentiated development and commercialization approaches

Segmentation reveals distinct development, adoption, and commercialization dynamics that require tailored strategies across product types, target animals, disease categories, administration routes, and distribution pathways. Based on Product, the field includes inactivated vaccines, live attenuated vaccines, mRNA vaccines, recombinant vaccines, and subunit vaccines, each presenting different R&D timelines, manufacturing complexities, and cold-chain dependencies; these differences inform prioritization decisions for pipeline investment and capacity planning. Based on Animal Type, the market spans companion animals and livestock animals, where the Companion Animals category further differentiates into cats and dogs, and the Livestock Animals category further differentiates into cattle, poultry, sheep, and swine; this segmentation underscores that clinical needs, dosing regimens, and distribution models vary substantially between household pets and production animals, driving distinct commercial channels and communication strategies.

Based on Disease Type, attention must be allocated across bacterial infections, fungal infections, parasitic infections, and viral infections. Within bacterial infections, clinical focus areas include clostridial diseases, E. coli, leptospirosis, and pasteurella, while parasitic infections break down into ectoparasites and endoparasites. Viral infections demand specialized responses to agents such as avian influenza virus, bovine viral diarrhea virus (BVDV), foot-and-mouth disease virus (FMDV), Newcastle disease virus, porcine reproductive and respiratory syndrome virus (PRRSV), and rabies virus. Each disease subset drives different antigen design approaches, regulatory pathways, and field efficacy considerations. Based on Route of Administration, vaccines are delivered as injectable vaccines and oral vaccines, with injectable vaccines further categorized by intramuscular, intravenous, and subcutaneous routes; administration route affects compliance, training requirements for administers, and formulation constraints. Based on Distribution Channel, suppliers reach end-users through online pharmacies, retail pharmacies, and veterinary clinics, and each channel imposes unique handling, labeling, and service expectations. Integrating these segmentation lenses enables more precise product positioning, targeted clinical trial designs, and differentiated go-to-market strategies that align with the operational realities of veterinarians and producers.

Distinct regional priorities and infrastructure realities driving differentiated policy, manufacturing, and distribution strategies across the Americas, EMEA, and Asia-Pacific landscapes

Regional dynamics frame distinct strategic priorities for vaccine developers, distributors, and policymakers, reflecting differences in regulatory regimes, production capacity, disease prevalence, and distribution infrastructure. In the Americas, there is a strong focus on regulatory harmonization, cold-chain modernization, and public-private partnerships to address both companion animal and livestock immunization needs. Regulatory agencies in this region emphasize demonstrable safety and efficacy, while industry actors pursue productivity gains through manufacturing automation and precision vaccination programs tied to surveillance data. Cross-border trade within the region supports consolidated production hubs, but recent policy shifts have incentivized greater supply diversification to reduce exposure to external shocks.

Europe, Middle East & Africa presents a mosaic of market conditions where advanced regulatory frameworks in some economies coexist with resource-constrained settings that require low-cost, thermostable formulations and decentralized distribution models. Demand in this region is influenced by strong animal welfare advocacy, stringent pathogen control standards, and a high level of veterinary professionalization in certain markets. Public health priorities drive collaborative initiatives for zoonotic disease prevention, while capacity gaps in parts of Africa and the Middle East create opportunities for novel delivery strategies and local manufacturing ventures.

Asia-Pacific continues to be a strategic focus due to its high livestock densities, diverse production systems, and rapidly modernizing veterinary sectors. Rapid urbanization, intensification of poultry and swine production, and persistent endemic and emerging viral threats place a premium on scalable vaccine solutions and rapid-response platforms. Governments in the region have shown interest in strengthening domestic biotech capabilities and in policies that support vaccine self-sufficiency, which creates an environment conducive to technology transfer, regional contract manufacturing, and collaborative surveillance networks. Across all regions, localized regulatory intelligence, disease profiling, and channel strategies are essential to unlocking adoption and sustaining immunization programs.

Market leaders and agile innovators are forging partnerships, securing specialized manufacturing capacity, and integrating services to convert technological advantage into durable commercial positioning

Competitive dynamics in the animal vaccines space are shaped by a mix of multinational firms, specialized biotech innovators, and contract manufacturers that provide flexible capacity. Established players continue to invest in portfolio diversification and manufacturing resilience, balancing legacy platforms such as inactivated and live attenuated vaccines with emerging technologies like mRNA and recombinant constructs. Specialized biotech entrants are advancing niche indications and platform capabilities, often partnering with contract development and manufacturing organizations to scale production rapidly and to de-risk capital-intensive facility builds. Meanwhile, contract manufacturers and service providers play an increasingly strategic role by offering modular, purpose-built capacity that shortens commercialization timelines and supports regional localization efforts.

Strategic collaborations, licensing agreements, and co-development models have become common, allowing organizations to combine scientific expertise, regulatory know-how, and distribution reach. Intellectual property around novel adjuvants, thermostable formulations, and antigen-display platforms is a critical differentiator, as is the ability to translate genomic surveillance insights into updated vaccine strains. Companies that integrate post-sale services-such as cold-chain monitoring, vaccination adherence platforms, and data analytics-enhance customer value and create stickiness with veterinarians and producers. In sum, the competitive landscape rewards agility in product innovation, manufacturing partnerships, and the ability to deliver end-to-end solutions that reduce operational friction for end-users.

Actionable strategic imperatives for manufacturers and stakeholders to accelerate innovation, diversify production, and strengthen regulatory and commercial partnerships for vaccine resilience

Industry leaders should adopt a multi-pronged strategy that accelerates technological translation while strengthening supply chain redundancy and stakeholder engagement. First, prioritize platform-agnostic R&D investments that can be re-targeted across multiple disease indications to maximize the return on scientific advances and to shorten the time to field deployment. Second, develop flexible manufacturing networks by qualifying multiple contract manufacturers across regions and by investing selectively in modular, single-use technologies that enable rapid scale-up and reduce changeover times. Third, design formulations and packaging with real-world distribution constraints in mind, emphasizing thermostability and simplified administration routes to broaden access in decentralized delivery settings.

Additionally, cultivate closer collaboration with regulatory authorities to pilot adaptive approval pathways for novel modalities and to align on post-approval evidence generation. Strengthen relationships with veterinarians through education, data-driven outcomes measurement, and integrated service offerings that support vaccination adherence and herd-level decision-making. Finally, embed trade-risk mitigation into commercial planning by diversifying supplier bases, negotiating flexible contracting terms, and engaging with policymakers to support incentives for domestic capacity where strategic. Executing on these recommendations will increase resilience, accelerate adoption, and create measurable value for animal health stakeholders across companion and production animal segments.

A validated, multi-source research approach combining stakeholder interviews, technical literature review, and supply chain and policy analysis to produce actionable insights grounded in operational realities

This research synthesis draws on a triangulated methodology combining primary stakeholder engagement, technical literature review, and supply chain and policy analysis to ensure robust, actionable findings. Primary inputs included structured interviews with veterinary clinicians, vaccine developers, contract manufacturers, and distribution channel leaders to capture operational realities, unmet needs, and strategic intent. Technical literature and regulatory guidance documents were reviewed to validate scientific trends, modality-specific considerations, and recent policy developments affecting vaccine development and authorization.

Complementary analysis assessed trade and supply chain implications by examining tariff schedules, public procurement practices, and logistical constraints that influence distribution decisions. Comparative regional assessments were informed by disease surveillance reporting and veterinary infrastructure profiling to contextualize adoption barriers and opportunities. Findings were synthesized through an iterative validation process with subject-matter experts to ensure that recommendations reflect practical feasibility and regulatory realism. Throughout, care was taken to avoid extrapolating into speculative market sizing, instead focusing on structural drivers, operational implications, and decision-useful insights for leaders in the animal vaccines ecosystem.

A concise synthesis of how innovation, policy shifts, and operational resilience must be aligned to realize the full potential of vaccines in protecting animal health and public safety

The convergence of scientific innovation, changing trade policies, and region-specific disease pressures presents both challenges and opportunities for the animal vaccines ecosystem. Advances in platform technologies and formulation science create pathways to more effective and accessible vaccines, yet these gains must be matched by investments in manufacturing flexibility, distribution resilience, and regulatory collaboration. Tariff shifts and geopolitical considerations have underscored the strategic importance of supply diversification and regional capacity, while evolving end-user expectations demand products that are not only efficacious but also practical to deploy in real-world veterinary settings.

Going forward, success will favor organizations that integrate technological agility with operational robustness and stakeholder-centric commercialization strategies. Collaboration across the value chain-from tech developers and contract manufacturers to veterinarians and distributors-will accelerate translational success and enhance impact. By aligning R&D priorities with pragmatic delivery solutions and policy engagement, industry actors can strengthen animal health outcomes, protect food systems, and reduce zoonotic risk in an increasingly interconnected world.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Animal Vaccines Market, by Product

  • 8.1. Inactivated Vaccines
  • 8.2. Live Attenuated Vaccines
  • 8.3. mRNA Vaccines
  • 8.4. Recombinant Vaccines
  • 8.5. Subunit Vaccines

9. Animal Vaccines Market, by Animal Type

  • 9.1. Companion Animals
    • 9.1.1. Cats
    • 9.1.2. Dogs
  • 9.2. Livestock Animals
    • 9.2.1. Cattle
    • 9.2.2. Poultry
    • 9.2.3. Sheep
    • 9.2.4. Swine

10. Animal Vaccines Market, by Disease Type

  • 10.1. Bacterial Infections
    • 10.1.1. Clostridial
    • 10.1.2. E. Coli
    • 10.1.3. Leptospirosis
    • 10.1.4. Pasteurella
  • 10.2. Fungal Infections
  • 10.3. Parasitic Infections
    • 10.3.1. Ectoparasites
    • 10.3.2. Endoparasites
  • 10.4. Viral Infections
    • 10.4.1. Avian Influenza Virus
    • 10.4.2. Bovine Viral Diarrhea Virus (BVDV)
    • 10.4.3. Foot-and-Mouth Disease Virus (FMDV)
    • 10.4.4. Newcastle Disease Virus
    • 10.4.5. Porcine Reproductive & Respiratory Syndrome Virus (PRRSV)
    • 10.4.6. Rabies Virus

11. Animal Vaccines Market, by Route of Administration

  • 11.1. Injectable Vaccines
    • 11.1.1. Intramuscular (IM)
    • 11.1.2. Intravenous (IV)
    • 11.1.3. Subcutaneous (SC)
  • 11.2. Oral Vaccines

12. Animal Vaccines Market, by Distribution Channel

  • 12.1. Online Pharmacies
  • 12.2. Retail Pharmacies
  • 12.3. Veterinary Clinics

13. Animal Vaccines Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Animal Vaccines Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Animal Vaccines Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. United States Animal Vaccines Market

17. China Animal Vaccines Market

18. Competitive Landscape

  • 18.1. Market Concentration Analysis, 2025
    • 18.1.1. Concentration Ratio (CR)
    • 18.1.2. Herfindahl Hirschman Index (HHI)
  • 18.2. Recent Developments & Impact Analysis, 2025
  • 18.3. Product Portfolio Analysis, 2025
  • 18.4. Benchmarking Analysis, 2025
  • 18.5. Biogenesis Bago S.A.
  • 18.6. BioVaxys Technology Corporation
  • 18.7. Boehringer Ingelheim International GmbH
  • 18.8. Brilliant Bio Pharma Private limited
  • 18.9. Ceva Sante Animale
  • 18.10. China Animal Husbandry Industry Co., Ltd.
  • 18.11. Dalan Animal Health
  • 18.12. Elanco Animal Health Inc.
  • 18.13. Endovac Animal Health, LLC by Immvac Inc.
  • 18.14. Hester Biosciences Limited
  • 18.15. HIPRA, S.A.
  • 18.16. Indian Immunologicals Limited
  • 18.17. Kemin Industries, Inc.
  • 18.18. Merck KGaA
  • 18.19. Neogen Corporation
  • 18.20. Phibro Animal Health Corporation
  • 18.21. SAN Vet Holding GmbH
  • 18.22. Sanofi S.A.
  • 18.23. Seppic S.A.
  • 18.24. Torigen Pharmaceuticals Inc.
  • 18.25. Vaxxinova GmbH
  • 18.26. VEROVACCiNES GmbH
  • 18.27. Vetigenics, LLC
  • 18.28. Vetoquinol SA
  • 18.29. Virbac, Inc.
  • 18.30. Zoetis Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL ANIMAL VACCINES MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL ANIMAL VACCINES MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL ANIMAL VACCINES MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL ANIMAL VACCINES MARKET SIZE, BY PRODUCT, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL ANIMAL VACCINES MARKET SIZE, BY ANIMAL TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL ANIMAL VACCINES MARKET SIZE, BY DISEASE TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL ANIMAL VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL ANIMAL VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL ANIMAL VACCINES MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL ANIMAL VACCINES MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL ANIMAL VACCINES MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. UNITED STATES ANIMAL VACCINES MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 13. CHINA ANIMAL VACCINES MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL ANIMAL VACCINES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL ANIMAL VACCINES MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL ANIMAL VACCINES MARKET SIZE, BY INACTIVATED VACCINES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL ANIMAL VACCINES MARKET SIZE, BY INACTIVATED VACCINES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL ANIMAL VACCINES MARKET SIZE, BY INACTIVATED VACCINES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL ANIMAL VACCINES MARKET SIZE, BY LIVE ATTENUATED VACCINES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL ANIMAL VACCINES MARKET SIZE, BY LIVE ATTENUATED VACCINES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL ANIMAL VACCINES MARKET SIZE, BY LIVE ATTENUATED VACCINES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL ANIMAL VACCINES MARKET SIZE, BY MRNA VACCINES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL ANIMAL VACCINES MARKET SIZE, BY MRNA VACCINES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL ANIMAL VACCINES MARKET SIZE, BY MRNA VACCINES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL ANIMAL VACCINES MARKET SIZE, BY RECOMBINANT VACCINES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL ANIMAL VACCINES MARKET SIZE, BY RECOMBINANT VACCINES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL ANIMAL VACCINES MARKET SIZE, BY RECOMBINANT VACCINES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL ANIMAL VACCINES MARKET SIZE, BY SUBUNIT VACCINES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL ANIMAL VACCINES MARKET SIZE, BY SUBUNIT VACCINES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL ANIMAL VACCINES MARKET SIZE, BY SUBUNIT VACCINES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL ANIMAL VACCINES MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL ANIMAL VACCINES MARKET SIZE, BY COMPANION ANIMALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL ANIMAL VACCINES MARKET SIZE, BY COMPANION ANIMALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL ANIMAL VACCINES MARKET SIZE, BY COMPANION ANIMALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL ANIMAL VACCINES MARKET SIZE, BY COMPANION ANIMALS, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL ANIMAL VACCINES MARKET SIZE, BY CATS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL ANIMAL VACCINES MARKET SIZE, BY CATS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL ANIMAL VACCINES MARKET SIZE, BY CATS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL ANIMAL VACCINES MARKET SIZE, BY DOGS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL ANIMAL VACCINES MARKET SIZE, BY DOGS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL ANIMAL VACCINES MARKET SIZE, BY DOGS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL ANIMAL VACCINES MARKET SIZE, BY LIVESTOCK ANIMALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL ANIMAL VACCINES MARKET SIZE, BY LIVESTOCK ANIMALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL ANIMAL VACCINES MARKET SIZE, BY LIVESTOCK ANIMALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL ANIMAL VACCINES MARKET SIZE, BY LIVESTOCK ANIMALS, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL ANIMAL VACCINES MARKET SIZE, BY CATTLE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL ANIMAL VACCINES MARKET SIZE, BY CATTLE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL ANIMAL VACCINES MARKET SIZE, BY CATTLE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL ANIMAL VACCINES MARKET SIZE, BY POULTRY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL ANIMAL VACCINES MARKET SIZE, BY POULTRY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL ANIMAL VACCINES MARKET SIZE, BY POULTRY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL ANIMAL VACCINES MARKET SIZE, BY SHEEP, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL ANIMAL VACCINES MARKET SIZE, BY SHEEP, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL ANIMAL VACCINES MARKET SIZE, BY SHEEP, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL ANIMAL VACCINES MARKET SIZE, BY SWINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL ANIMAL VACCINES MARKET SIZE, BY SWINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL ANIMAL VACCINES MARKET SIZE, BY SWINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL ANIMAL VACCINES MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL ANIMAL VACCINES MARKET SIZE, BY BACTERIAL INFECTIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL ANIMAL VACCINES MARKET SIZE, BY BACTERIAL INFECTIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL ANIMAL VACCINES MARKET SIZE, BY BACTERIAL INFECTIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL ANIMAL VACCINES MARKET SIZE, BY BACTERIAL INFECTIONS, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL ANIMAL VACCINES MARKET SIZE, BY CLOSTRIDIAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL ANIMAL VACCINES MARKET SIZE, BY CLOSTRIDIAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL ANIMAL VACCINES MARKET SIZE, BY CLOSTRIDIAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL ANIMAL VACCINES MARKET SIZE, BY E. COLI, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL ANIMAL VACCINES MARKET SIZE, BY E. COLI, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL ANIMAL VACCINES MARKET SIZE, BY E. COLI, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL ANIMAL VACCINES MARKET SIZE, BY LEPTOSPIROSIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL ANIMAL VACCINES MARKET SIZE, BY LEPTOSPIROSIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL ANIMAL VACCINES MARKET SIZE, BY LEPTOSPIROSIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL ANIMAL VACCINES MARKET SIZE, BY PASTEURELLA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL ANIMAL VACCINES MARKET SIZE, BY PASTEURELLA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL ANIMAL VACCINES MARKET SIZE, BY PASTEURELLA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL ANIMAL VACCINES MARKET SIZE, BY FUNGAL INFECTIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL ANIMAL VACCINES MARKET SIZE, BY FUNGAL INFECTIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL ANIMAL VACCINES MARKET SIZE, BY FUNGAL INFECTIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL ANIMAL VACCINES MARKET SIZE, BY PARASITIC INFECTIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL ANIMAL VACCINES MARKET SIZE, BY PARASITIC INFECTIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL ANIMAL VACCINES MARKET SIZE, BY PARASITIC INFECTIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL ANIMAL VACCINES MARKET SIZE, BY PARASITIC INFECTIONS, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL ANIMAL VACCINES MARKET SIZE, BY ECTOPARASITES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL ANIMAL VACCINES MARKET SIZE, BY ECTOPARASITES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL ANIMAL VACCINES MARKET SIZE, BY ECTOPARASITES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL ANIMAL VACCINES MARKET SIZE, BY ENDOPARASITES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL ANIMAL VACCINES MARKET SIZE, BY ENDOPARASITES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL ANIMAL VACCINES MARKET SIZE, BY ENDOPARASITES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL ANIMAL VACCINES MARKET SIZE, BY VIRAL INFECTIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL ANIMAL VACCINES MARKET SIZE, BY VIRAL INFECTIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL ANIMAL VACCINES MARKET SIZE, BY VIRAL INFECTIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL ANIMAL VACCINES MARKET SIZE, BY VIRAL INFECTIONS, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL ANIMAL VACCINES MARKET SIZE, BY AVIAN INFLUENZA VIRUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL ANIMAL VACCINES MARKET SIZE, BY AVIAN INFLUENZA VIRUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL ANIMAL VACCINES MARKET SIZE, BY AVIAN INFLUENZA VIRUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL ANIMAL VACCINES MARKET SIZE, BY BOVINE VIRAL DIARRHEA VIRUS (BVDV), BY REGION, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL ANIMAL VACCINES MARKET SIZE, BY BOVINE VIRAL DIARRHEA VIRUS (BVDV), BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL ANIMAL VACCINES MARKET SIZE, BY BOVINE VIRAL DIARRHEA VIRUS (BVDV), BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL ANIMAL VACCINES MARKET SIZE, BY FOOT-AND-MOUTH DISEASE VIRUS (FMDV), BY REGION, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL ANIMAL VACCINES MARKET SIZE, BY FOOT-AND-MOUTH DISEASE VIRUS (FMDV), BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL ANIMAL VACCINES MARKET SIZE, BY FOOT-AND-MOUTH DISEASE VIRUS (FMDV), BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL ANIMAL VACCINES MARKET SIZE, BY NEWCASTLE DISEASE VIRUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL ANIMAL VACCINES MARKET SIZE, BY NEWCASTLE DISEASE VIRUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL ANIMAL VACCINES MARKET SIZE, BY NEWCASTLE DISEASE VIRUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL ANIMAL VACCINES MARKET SIZE, BY PORCINE REPRODUCTIVE & RESPIRATORY SYNDROME VIRUS (PRRSV), BY REGION, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL ANIMAL VACCINES MARKET SIZE, BY PORCINE REPRODUCTIVE & RESPIRATORY SYNDROME VIRUS (PRRSV), BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL ANIMAL VACCINES MARKET SIZE, BY PORCINE REPRODUCTIVE & RESPIRATORY SYNDROME VIRUS (PRRSV), BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL ANIMAL VACCINES MARKET SIZE, BY RABIES VIRUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL ANIMAL VACCINES MARKET SIZE, BY RABIES VIRUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL ANIMAL VACCINES MARKET SIZE, BY RABIES VIRUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL ANIMAL VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL ANIMAL VACCINES MARKET SIZE, BY INJECTABLE VACCINES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL ANIMAL VACCINES MARKET SIZE, BY INJECTABLE VACCINES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL ANIMAL VACCINES MARKET SIZE, BY INJECTABLE VACCINES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL ANIMAL VACCINES MARKET SIZE, BY INJECTABLE VACCINES, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL ANIMAL VACCINES MARKET SIZE, BY INTRAMUSCULAR (IM), BY REGION, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL ANIMAL VACCINES MARKET SIZE, BY INTRAMUSCULAR (IM), BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL ANIMAL VACCINES MARKET SIZE, BY INTRAMUSCULAR (IM), BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL ANIMAL VACCINES MARKET SIZE, BY INTRAVENOUS (IV), BY REGION, 2018-2032 (USD MILLION)
  • TABLE 106. GLOBAL ANIMAL VACCINES MARKET SIZE, BY INTRAVENOUS (IV), BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL ANIMAL VACCINES MARKET SIZE, BY INTRAVENOUS (IV), BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 108. GLOBAL ANIMAL VACCINES MARKET SIZE, BY SUBCUTANEOUS (SC), BY REGION, 2018-2032 (USD MILLION)
  • TABLE 109. GLOBAL ANIMAL VACCINES MARKET SIZE, BY SUBCUTANEOUS (SC), BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 110. GLOBAL ANIMAL VACCINES MARKET SIZE, BY SUBCUTANEOUS (SC), BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 111. GLOBAL ANIMAL VACCINES MARKET SIZE, BY ORAL VACCINES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 112. GLOBAL ANIMAL VACCINES MARKET SIZE, BY ORAL VACCINES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 113. GLOBAL ANIMAL VACCINES MARKET SIZE, BY ORAL VACCINES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 114. GLOBAL ANIMAL VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 115. GLOBAL ANIMAL VACCINES MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 116. GLOBAL ANIMAL VACCINES MARKET SIZE, BY ONLINE PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 117. GLOBAL ANIMAL VACCINES MARKET SIZE, BY ONLINE PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 118. GLOBAL ANIMAL VACCINES MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 119. GLOBAL ANIMAL VACCINES MARKET SIZE, BY RETAIL PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 120. GLOBAL ANIMAL VACCINES MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 121. GLOBAL ANIMAL VACCINES MARKET SIZE, BY VETERINARY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 122. GLOBAL ANIMAL VACCINES MARKET SIZE, BY VETERINARY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 123. GLOBAL ANIMAL VACCINES MARKET SIZE, BY VETERINARY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 124. GLOBAL ANIMAL VACCINES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 125. AMERICAS ANIMAL VACCINES MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 126. AMERICAS ANIMAL VACCINES MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 127. AMERICAS ANIMAL VACCINES MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 128. AMERICAS ANIMAL VACCINES MARKET SIZE, BY COMPANION ANIMALS, 2018-2032 (USD MILLION)
  • TABLE 129. AMERICAS ANIMAL VACCINES MARKET SIZE, BY LIVESTOCK ANIMALS, 2018-2032 (USD MILLION)
  • TABLE 130. AMERICAS ANIMAL VACCINES MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 131. AMERICAS ANIMAL VACCINES MARKET SIZE, BY BACTERIAL INFECTIONS, 2018-2032 (USD MILLION)
  • TABLE 132. AMERICAS ANIMAL VACCINES MARKET SIZE, BY PARASITIC INFECTIONS, 2018-2032 (USD MILLION)
  • TABLE 133. AMERICAS ANIMAL VACCINES MARKET SIZE, BY VIRAL INFECTIONS, 2018-2032 (USD MILLION)
  • TABLE 134. AMERICAS ANIMAL VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 135. AMERICAS ANIMAL VACCINES MARKET SIZE, BY INJECTABLE VACCINES, 2018-2032 (USD MILLION)
  • TABLE 136. AMERICAS ANIMAL VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 137. NORTH AMERICA ANIMAL VACCINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 138. NORTH AMERICA ANIMAL VACCINES MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 139. NORTH AMERICA ANIMAL VACCINES MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 140. NORTH AMERICA ANIMAL VACCINES MARKET SIZE, BY COMPANION ANIMALS, 2018-2032 (USD MILLION)
  • TABLE 141. NORTH AMERICA ANIMAL VACCINES MARKET SIZE, BY LIVESTOCK ANIMALS, 2018-2032 (USD MILLION)
  • TABLE 142. NORTH AMERICA ANIMAL VACCINES MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 143. NORTH AMERICA ANIMAL VACCINES MARKET SIZE, BY BACTERIAL INFECTIONS, 2018-2032 (USD MILLION)
  • TABLE 144. NORTH AMERICA ANIMAL VACCINES MARKET SIZE, BY PARASITIC INFECTIONS, 2018-2032 (USD MILLION)
  • TABLE 145. NORTH AMERICA ANIMAL VACCINES MARKET SIZE, BY VIRAL INFECTIONS, 2018-2032 (USD MILLION)
  • TABLE 146. NORTH AMERICA ANIMAL VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 147. NORTH AMERICA ANIMAL VACCINES MARKET SIZE, BY INJECTABLE VACCINES, 2018-2032 (USD MILLION)
  • TABLE 148. NORTH AMERICA ANIMAL VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 149. LATIN AMERICA ANIMAL VACCINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 150. LATIN AMERICA ANIMAL VACCINES MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 151. LATIN AMERICA ANIMAL VACCINES MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 152. LATIN AMERICA ANIMAL VACCINES MARKET SIZE, BY COMPANION ANIMALS, 2018-2032 (USD MILLION)
  • TABLE 153. LATIN AMERICA ANIMAL VACCINES MARKET SIZE, BY LIVESTOCK ANIMALS, 2018-2032 (USD MILLION)
  • TABLE 154. LATIN AMERICA ANIMAL VACCINES MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 155. LATIN AMERICA ANIMAL VACCINES MARKET SIZE, BY BACTERIAL INFECTIONS, 2018-2032 (USD MILLION)
  • TABLE 156. LATIN AMERICA ANIMAL VACCINES MARKET SIZE, BY PARASITIC INFECTIONS, 2018-2032 (USD MILLION)
  • TABLE 157. LATIN AMERICA ANIMAL VACCINES MARKET SIZE, BY VIRAL INFECTIONS, 2018-2032 (USD MILLION)
  • TABLE 158. LATIN AMERICA ANIMAL VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 159. LATIN AMERICA ANIMAL VACCINES MARKET SIZE, BY INJECTABLE VACCINES, 2018-2032 (USD MILLION)
  • TABLE 160. LATIN AMERICA ANIMAL VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 161. EUROPE, MIDDLE EAST & AFRICA ANIMAL VACCINES MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 162. EUROPE, MIDDLE EAST & AFRICA ANIMAL VACCINES MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 163. EUROPE, MIDDLE EAST & AFRICA ANIMAL VACCINES MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 164. EUROPE, MIDDLE EAST & AFRICA ANIMAL VACCINES MARKET SIZE, BY COMPANION ANIMALS, 2018-2032 (USD MILLION)
  • TABLE 165. EUROPE, MIDDLE EAST & AFRICA ANIMAL VACCINES MARKET SIZE, BY LIVESTOCK ANIMALS, 2018-2032 (USD MILLION)
  • TABLE 166. EUROPE, MIDDLE EAST & AFRICA ANIMAL VACCINES MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 167. EUROPE, MIDDLE EAST & AFRICA ANIMAL VACCINES MARKET SIZE, BY BACTERIAL INFECTIONS, 2018-2032 (USD MILLION)
  • TABLE 168. EUROPE, MIDDLE EAST & AFRICA ANIMAL VACCINES MARKET SIZE, BY PARASITIC INFECTIONS, 2018-2032 (USD MILLION)
  • TABLE 169. EUROPE, MIDDLE EAST & AFRICA ANIMAL VACCINES MARKET SIZE, BY VIRAL INFECTIONS, 2018-2032 (USD MILLION)
  • TABLE 170. EUROPE, MIDDLE EAST & AFRICA ANIMAL VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 171. EUROPE, MIDDLE EAST & AFRICA ANIMAL VACCINES MARKET SIZE, BY INJECTABLE VACCINES, 2018-2032 (USD MILLION)
  • TABLE 172. EUROPE, MIDDLE EAST & AFRICA ANIMAL VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 173. EUROPE ANIMAL VACCINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 174. EUROPE ANIMAL VACCINES MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 175. EUROPE ANIMAL VACCINES MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 176. EUROPE ANIMAL VACCINES MARKET SIZE, BY COMPANION ANIMALS, 2018-2032 (USD MILLION)
  • TABLE 177. EUROPE ANIMAL VACCINES MARKET SIZE, BY LIVESTOCK ANIMALS, 2018-2032 (USD MILLION)
  • TABLE 178. EUROPE ANIMAL VACCINES MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 179. EUROPE ANIMAL VACCINES MARKET SIZE, BY BACTERIAL INFECTIONS, 2018-2032 (USD MILLION)
  • TABLE 180. EUROPE ANIMAL VACCINES MARKET SIZE, BY PARASITIC INFECTIONS, 2018-2032 (USD MILLION)
  • TABLE 181. EUROPE ANIMAL VACCINES MARKET SIZE, BY VIRAL INFECTIONS, 2018-2032 (USD MILLION)
  • TABLE 182. EUROPE ANIMAL VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 183. EUROPE ANIMAL VACCINES MARKET SIZE, BY INJECTABLE VACCINES, 2018-2032 (USD MILLION)
  • TABLE 184. EUROPE ANIMAL VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 185. MIDDLE EAST ANIMAL VACCINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 186. MIDDLE EAST ANIMAL VACCINES MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 187. MIDDLE EAST ANIMAL VACCINES MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 188. MIDDLE EAST ANIMAL VACCINES MARKET SIZE, BY COMPANION ANIMALS, 2018-2032 (USD MILLION)
  • TABLE 189. MIDDLE EAST ANIMAL VACCINES MARKET SIZE, BY LIVESTOCK ANIMALS, 2018-2032 (USD MILLION)
  • TABLE 190. MIDDLE EAST ANIMAL VACCINES MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 191. MIDDLE EAST ANIMAL VACCINES MARKET SIZE, BY BACTERIAL INFECTIONS, 2018-2032 (USD MILLION)
  • TABLE 192. MIDDLE EAST ANIMAL VACCINES MARKET SIZE, BY PARASITIC INFECTIONS, 2018-2032 (USD MILLION)
  • TABLE 193. MIDDLE EAST ANIMAL VACCINES MARKET SIZE, BY VIRAL INFECTIONS, 2018-2032 (USD MILLION)
  • TABLE 194. MIDDLE EAST ANIMAL VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 195. MIDDLE EAST ANIMAL VACCINES MARKET SIZE, BY INJECTABLE VACCINES, 2018-2032 (USD MILLION)
  • TABLE 196. MIDDLE EAST ANIMAL VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 197. AFRICA ANIMAL VACCINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 198. AFRICA ANIMAL VACCINES MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 199. AFRICA ANIMAL VACCINES MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 200. AFRICA ANIMAL VACCINES MARKET SIZE, BY COMPANION ANIMALS, 2018-2032 (USD MILLION)
  • TABLE 201. AFRICA ANIMAL VACCINES MARKET SIZE, BY LIVESTOCK ANIMALS, 2018-2032 (USD MILLION)
  • TABLE 202. AFRICA ANIMAL VACCINES MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 203. AFRICA ANIMAL VACCINES MARKET SIZE, BY BACTERIAL INFECTIONS, 2018-2032 (USD MILLION)
  • TABLE 204. AFRICA ANIMAL VACCINES MARKET SIZE, BY PARASITIC INFECTIONS, 2018-2032 (USD MILLION)
  • TABLE 205. AFRICA ANIMAL VACCINES MARKET SIZE, BY VIRAL INFECTIONS, 2018-2032 (USD MILLION)
  • TABLE 206. AFRICA ANIMAL VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 207. AFRICA ANIMAL VACCINES MARKET SIZE, BY INJECTABLE VACCINES, 2018-2032 (USD MILLION)
  • TABLE 208. AFRICA ANIMAL VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 209. ASIA-PACIFIC ANIMAL VACCINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 210. ASIA-PACIFIC ANIMAL VACCINES MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 211. ASIA-PACIFIC ANIMAL VACCINES MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 212. ASIA-PACIFIC ANIMAL VACCINES MARKET SIZE, BY COMPANION ANIMALS, 2018-2032 (USD MILLION)
  • TABLE 213. ASIA-PACIFIC ANIMAL VACCINES MARKET SIZE, BY LIVESTOCK ANIMALS, 2018-2032 (USD MILLION)
  • TABLE 214. ASIA-PACIFIC ANIMAL VACCINES MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 215. ASIA-PACIFIC ANIMAL VACCINES MARKET SIZE, BY BACTERIAL INFECTIONS, 2018-2032 (USD MILLION)
  • TABLE 216. ASIA-PACIFIC ANIMAL VACCINES MARKET SIZE, BY PARASITIC INFECTIONS, 2018-2032 (USD MILLION)
  • TABLE 217. ASIA-PACIFIC ANIMAL VACCINES MARKET SIZE, BY VIRAL INFECTIONS, 2018-2032 (USD MILLION)
  • TABLE 218. ASIA-PACIFIC ANIMAL VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 219. ASIA-PACIFIC ANIMAL VACCINES MARKET SIZE, BY INJECTABLE VACCINES, 2018-2032 (USD MILLION)
  • TABLE 220. ASIA-PACIFIC ANIMAL VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 221. GLOBAL ANIMAL VACCINES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 222. ASEAN ANIMAL VACCINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 223. ASEAN ANIMAL VACCINES MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 224. ASEAN ANIMAL VACCINES MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 225. ASEAN ANIMAL VACCINES MARKET SIZE, BY COMPANION ANIMALS, 2018-2032 (USD MILLION)
  • TABLE 226. ASEAN ANIMAL VACCINES MARKET SIZE, BY LIVESTOCK ANIMALS, 2018-2032 (USD MILLION)
  • TABLE 227. ASEAN ANIMAL VACCINES MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 228. ASEAN ANIMAL VACCINES MARKET SIZE, BY BACTERIAL INFECTIONS, 2018-2032 (USD MILLION)
  • TABLE 229. ASEAN ANIMAL VACCINES MARKET SIZE, BY PARASITIC INFECTIONS, 2018-2032 (USD MILLION)
  • TABLE 230. ASEAN ANIMAL VACCINES MARKET SIZE, BY VIRAL INFECTIONS, 2018-2032 (USD MILLION)
  • TABLE 231. ASEAN ANIMAL VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 232. ASEAN ANIMAL VACCINES MARKET SIZE, BY INJECTABLE VACCINES, 2018-2032 (USD MILLION)
  • TABLE 233. ASEAN ANIMAL VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 234. GCC ANIMAL VACCINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 235. GCC ANIMAL VACCINES MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 236. GCC ANIMAL VACCINES MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 237. GCC ANIMAL VACCINES MARKET SIZE, BY COMPANION ANIMALS, 2018-2032 (USD MILLION)
  • TABLE 238. GCC ANIMAL VACCINES MARKET SIZE, BY LIVESTOCK ANIMALS, 2018-2032 (USD MILLION)
  • TABLE 239. GCC ANIMAL VACCINES MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 240. GCC ANIMAL VACCINES MARKET SIZE, BY BACTERIAL INFECTIONS, 2018-2032 (USD MILLION)
  • TABLE 241. GCC ANIMAL VACCINES MARKET SIZE, BY PARASITIC INFECTIONS, 2018-2032 (USD MILLION)
  • TABLE 242. GCC ANIMAL VACCINES MARKET SIZE, BY VIRAL INFECTIONS, 2018-2032 (USD MILLION)
  • TABLE 243. GCC ANIMAL VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 244. GCC ANIMAL VACCINES MARKET SIZE, BY INJECTABLE VACCINES, 2018-2032 (USD MILLION)
  • TABLE 245. GCC ANIMAL VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 246. EUROPEAN UNION ANIMAL VACCINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 247. EUROPEAN UNION ANIMAL VACCINES MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 248. EUROPEAN UNION ANIMAL VACCINES MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 249. EUROPEAN UNION ANIMAL VACCINES MARKET SIZE, BY COMPANION ANIMALS, 2018-2032 (USD MILLION)
  • TABLE 250. EUROPEAN UNION ANIMAL VACCINES MARKET SIZE, BY LIVESTOCK ANIMALS, 2018-2032 (USD MILLION)
  • TABLE 251. EUROPEAN UNION ANIMAL VACCINES MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 252. EUROPEAN UNION ANIMAL VACCINES MARKET SIZE, BY BACTERIAL INFECTIONS, 2018-2032 (USD MILLION)
  • TABLE 253. EUROPEAN UNION ANIMAL VACCINES MARKET SIZE, BY PARASITIC INFECTIONS, 2018-2032 (USD MILLION)
  • TABLE 254. EUROPEAN UNION ANIMAL VACCINES MARKET SIZE, BY VIRAL INFECTIONS, 2018-2032 (USD MILLION)
  • TABLE 255. EUROPEAN UNION ANIMAL VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 256. EUROPEAN UNION ANIMAL VACCINES MARKET SIZE, BY INJECTABLE VACCINES, 2018-2032 (USD MILLION)
  • TABLE 257. EUROPEAN UNION ANIMAL VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 258. BRICS ANIMAL VACCINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 259. BRICS ANIMAL VACCINES MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 260. BRICS ANIMAL VACCINES MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 261. BRICS ANIMAL VACCINES MARKET SIZE, BY COMPANION ANIMALS, 2018-2032 (USD MILLION)
  • TABLE 262. BRICS ANIMAL VACCINES MARKET SIZE, BY LIVESTOCK ANIMALS, 2018-2032 (USD MILLION)
  • TABLE 263. BRICS ANIMAL VACCINES MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 264. BRICS ANIMAL VACCINES MARKET SIZE, BY BACTERIAL INFECTIONS, 2018-2032 (USD MILLION)
  • TABLE 265. BRICS ANIMAL VACCINES MARKET SIZE, BY PARASITIC INFECTIONS, 2018-2032 (USD MILLION)
  • TABLE 266. BRICS ANIMAL VACCINES MARKET SIZE, BY VIRAL INFECTIONS, 2018-2032 (USD MILLION)
  • TABLE 267. BRICS ANIMAL VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 268. BRICS ANIMAL VACCINES MARKET SIZE, BY INJECTABLE VACCINES, 2018-2032 (USD MILLION)
  • TABLE 269. BRICS ANIMAL VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 270. G7 ANIMAL VACCINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 271. G7 ANIMAL VACCINES MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 272. G7 ANIMAL VACCINES MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 273. G7 ANIMAL VACCINES MARKET SIZE, BY COMPANION ANIMALS, 2018-2032 (USD MILLION)
  • TABLE 274. G7 ANIMAL VACCINES MARKET SIZE, BY LIVESTOCK ANIMALS, 2018-2032 (USD MILLION)
  • TABLE 275. G7 ANIMAL VACCINES MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 276. G7 ANIMAL VACCINES MARKET SIZE, BY BACTERIAL INFECTIONS, 2018-2032 (USD MILLION)
  • TABLE 277. G7 ANIMAL VACCINES MARKET SIZE, BY PARASITIC INFECTIONS, 2018-2032 (USD MILLION)
  • TABLE 278. G7 ANIMAL VACCINES MARKET SIZE, BY VIRAL INFECTIONS, 2018-2032 (USD MILLION)
  • TABLE 279. G7 ANIMAL VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 280. G7 ANIMAL VACCINES MARKET SIZE, BY INJECTABLE VACCINES, 2018-2032 (USD MILLION)
  • TABLE 281. G7 ANIMAL VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 282. NATO ANIMAL VACCINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 283. NATO ANIMAL VACCINES MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 284. NATO ANIMAL VACCINES MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 285. NATO ANIMAL VACCINES MARKET SIZE, BY COMPANION ANIMALS, 2018-2032 (USD MILLION)
  • TABLE 286. NATO ANIMAL VACCINES MARKET SIZE, BY LIVESTOCK ANIMALS, 2018-2032 (USD MILLION)
  • TABLE 287. NATO ANIMAL VACCINES MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 288. NATO ANIMAL VACCINES MARKET SIZE, BY BACTERIAL INFECTIONS, 2018-2032 (USD MILLION)
  • TABLE 289. NATO ANIMAL VACCINES MARKET SIZE, BY PARASITIC INFECTIONS, 2018-2032 (USD MILLION)
  • TABLE 290. NATO ANIMAL VACCINES MARKET SIZE, BY VIRAL INFECTIONS, 2018-2032 (USD MILLION)
  • TABLE 291. NATO ANIMAL VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 292. NATO ANIMAL VACCINES MARKET SIZE, BY INJECTABLE VACCINES, 2018-2032 (USD MILLION)
  • TABLE 293. NATO ANIMAL VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 294. GLOBAL ANIMAL VACCINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 295. UNITED STATES ANIMAL VACCINES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 296. UNITED STATES ANIMAL VACCINES MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 297. UNITED STATES ANIMAL VACCINES MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 298. UNITED STATES ANIMAL VACCINES MARKET SIZE, BY COMPANION ANIMALS, 2018-2032 (USD MILLION)
  • TABLE 299. UNITED STATES ANIMAL VACCINES MARKET SIZE, BY LIVESTOCK ANIMALS, 2018-2032 (USD MILLION)
  • TABLE 300. UNITED STATES ANIMAL VACCINES MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 301. UNITED STATES ANIMAL VACCINES MARKET SIZE, BY BACTERIAL INFECTIONS, 2018-2032 (USD MILLION)
  • TABLE 302. UNITED STATES ANIMAL VACCINES MARKET SIZE, BY PARASITIC INFECTIONS, 2018-2032 (USD MILLION)
  • TABLE 303. UNITED STATES ANIMAL VACCINES MARKET SIZE, BY VIRAL INFECTIONS, 2018-2032 (USD MILLION)
  • TABLE 304. UNITED STATES ANIMAL VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 305. UNITED STATES ANIMAL VACCINES MARKET SIZE, BY INJECTABLE VACCINES, 2018-2032 (USD MILLION)
  • TABLE 306. UNITED STATES ANIMAL VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 307. CHINA ANIMAL VACCINES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 308. CHINA ANIMAL VACCINES MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 309. CHINA ANIMAL VACCINES MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 310. CHINA ANIMAL VACCINES MARKET SIZE, BY COMPANION ANIMALS, 2018-2032 (USD MILLION)
  • TABLE 311. CHINA ANIMAL VACCINES MARKET SIZE, BY LIVESTOCK ANIMALS, 2018-2032 (USD MILLION)
  • TABLE 312. CHINA ANIMAL VACCINES MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 313. CHINA ANIMAL VACCINES MARKET SIZE, BY BACTERIAL INFECTIONS, 2018-2032 (USD MILLION)
  • TABLE 314. CHINA ANIMAL VACCINES MARKET SIZE, BY PARASITIC INFECTIONS, 2018-2032 (USD MILLION)
  • TABLE 315. CHINA ANIMAL VACCINES MARKET SIZE, BY VIRAL INFECTIONS, 2018-2032 (USD MILLION)
  • TABLE 316. CHINA ANIMAL VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 317. CHINA ANIMAL VACCINES MARKET SIZE, BY INJECTABLE VACCINES, 2018-2032 (USD MILLION)
  • TABLE 318. CHINA ANIMAL VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)